Inmode Ltd
NASDAQ:INMD
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IL |
|
Inmode Ltd
NASDAQ:INMD
|
875.6m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
202.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
178.4B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
148B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
124.9B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
113.5B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.8B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
52.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.3B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
50.3B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.3B USD |
Loading...
|
Market Distribution
| Min | -11 239.1% |
| 30th Percentile | 17.6% |
| Median | 29.8% |
| 70th Percentile | 50.4% |
| Max | 208.2% |
Other Profitability Ratios
Inmode Ltd
Glance View
InMode Ltd., founded in 2008, has emerged as a dynamic player in the field of minimally invasive aesthetic medical treatments. Born during a period where the health and beauty sectors were experiencing rapid technological innovation, the company quickly carved a niche for itself by addressing a clear market need: the rising demand for non-surgical procedures. At its heart, InMode merges the precision of medical technology with the principles of aesthetic enhancement. Its primary offerings revolve around radio-frequency-based devices that healthcare providers use to achieve results that traditionally required more invasive techniques. This includes skin tightening, fat reduction, and body contouring solutions, all tailored to meet the growing consumer appetite for treatments that carry less downtime and risk compared to conventional surgery. The company monetizes its expertise by manufacturing and selling these state-of-the-art devices to a diverse group of users, ranging from dermatologists and plastic surgeons to aesthetic practices. InMode's revenue streams are bolstered by not only the direct sale of these devices but also by ongoing client relationships through service agreements and consumable products that are essential for their machine operation. It is a model that ensures continuous engagement with their clients, providing both stability and growth in revenue. By focusing on innovation and efficacy, InMode has successfully captured a significant share of the aesthetic medical market, embodying a business strategy that combines cutting-edge technology with practical solutions to consumer needs.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Inmode Ltd is 78.5%, which is below its 3-year median of 81.6%.
Over the last 3 years, Inmode Ltd’s Gross Margin has decreased from 83.8% to 78.5%. During this period, it reached a low of 78.5% on Jan 1, 2026 and a high of 83.9% on Jun 30, 2023.